Akonni Biosystems inks agreement with USARMIID

Akonni Biosystems, a molecular diagnostics company and developer of low-cost, rapid and highly scalable solutions for the testing of infectious diseases, has inked a license agreement with the U.S. Army Medical Research Institute of Infectious Diseases.

The agreement gives Akonni full access to nucleic acid sequences, probes and primers for many of the most important and deadly biological threat agents. By gaining access to this content, Akonni will be able to rapidly commercialize multiple tests to be used in research and in vitro diagnostics situations for global bio-security applications, One Med Place reports.

The TruSentry System was recently launched by Akonni as a low-cost and rapid genetic screening method on a microarray. This highly automated solution gives scientists the ability to analyze more than 3,000 samples a day for genetic markers. It is designed for government institutions that are seeking to increase their capacity for the quick identification of infectious microorganisms and drug resistant variants at a much lower cost.

Akonni Biosystems, founded in 2003, has over 20 patents issued with an additional 13 others pending. The core technology of the company is based on work developed at Engelhardt Institute of Molecular Biology and the Argonne National Laboratory, according to One Med Place. It also uses gel-drop array technologies that have been optimized for medical applications.

The USAMRIID is the lead medical research laboratory for the U.S. Department of Defense’s Biological Defense Research Program, which is key for the government in both national defense and in infectious disease research.